PMS-Iron Sucrose · DIN 02502917 · 20 mg/mL · injection solution-5mL Pk (Preservative-Free)
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, August 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, August 31, 2026 ↗) Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Iron sucrose
Brand(s): Venofer, PMS Iron Sucrose
DOSAGE FORM/ STRENGTH: 20 mg/mL Injectable
For the treatment of iron-deficiency anemia confirmed by bloodwork where the patient
has a demonstrated intolerance1 to oral iron therapy2 OR has not responded to adequate
therapy with oral iron2.
1Intolerance must be described.
2Provide name of iron salt, dose, duration of therapy, response etc.
Duration of Approval: 1 year
Renewals will be considered on a case-by-case basis.
Duration of Approval: 2 years
22
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 22, record 3, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
(ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated October 05, 2026 ↗)1 brand, same coverage
PMS-Iron Sucrose · DIN 02502917
Manufacturer: Pharmascience Inc.; listing date 2021-03-29
Health Canada: Marketed since 2021-01-12 · brand PMS-IRON SUCROSE · ATC B03AC IRON, PARENTERAL PREPARATIONS · form Solution · route Intravenous · ingredients IRON (IRON SUCROSE) 20 MG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Iron Sucrose: Formulary list price $27.50 per unit (the source does not state the unit; exact figure $27.5000). What the ministry pays, not the patient.
Ministry pays: $27.5000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502917)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02502917).
DIN 02502917: PMS-Iron Sucrose
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 200400023; group id 250; item number 0442; lccId None; manufacturer id PMS
Source form: Inj Sol-5mL Pk (Preservative-Free); strength: 20mg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $27.5000; ministry $27.5000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502917
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99244
Interchangeable products
Venofer · DIN 02243716 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502917
Shortage record checked October 6, 2026